OS 2966

Drug Profile

OS 2966

Alternative Names: OS2966

Latest Information Update: 27 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoSynergy
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD29 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ebola virus infections; Glioblastoma; Solid tumours

Most Recent Events

  • 16 Dec 2014 Preclinical trials in Ebola virus infections in USA (unspecified route)
  • 12 Aug 2014 OS 2966 receives Orphan Drug status for Glioblastoma in USA
  • 17 Dec 2013 Preclinical trials in Glioblastoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top